Sirion drug outperforms Allergan agent in uveitis trial

Article

Sirion has announced the preliminary results of the clinical trial comparing the safety and efficacy of Durezol (difluprednate ophthalmic emulsion; Sirion) with that of Pred Forte (prednisolone acetate ophthalmic suspension; Allergan) for the treatment of anterior segment uveitis.

Sirion has announced the preliminary results of the clinical trial comparing the safety and efficacy of Durezol (difluprednate ophthalmic emulsion; Sirion) with that of Pred Forte (prednisolone acetate ophthalmic suspension; Allergan) for the treatment of anterior segment uveitis.

The multicentre, randomized, double-masked trial enrolled subjects with endogenous anterior uveitis (n=90). The study assessed Durezol 0.05% administered four times daily and compared the results with those gained for Pred Forte 1% dosed eight times daily. Both treatment arms had the same dosing regime: 14 days of treatment, followed by 14 days of tapered half doses, and a further 14 days of follow-up.

At Day 14, the reductions in anterior chamber (AC) cell grades were 2.1 and 1.9 for the Durezol and Pred Forte groups, respectively. Symptoms associated with anterior inflammation were reduced by 76% and 71% at Day 14 for the Durezol and Pred Forte groups, respectively. Pain, assessed using a Visual Analogue Scale, was reduced at Day 7 by 71% and 64% for the Durezol and Pred Forte groups, respectively. In both the Durezol and the Pred Forte groups, two patients experienced a statistically significant increase in intraocular pressure (IOP). 12.5% of Pred Forte patients withdrew from the study due to lack of efficacy and 0% of Durezol patients withdrew for this reason.

Durezol is currently indicated for postoperative inflammation and pain. Sirion now plans to combine this trial data with other results from a Japanese study to support the filing of a supplemental New Drug Application (sNDA) for anterior uveitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.